MEDIX, God. 17 Br. 96  •  Pregledni članak  •  Kardiologija HR ENG

Mišićne nuspojave i visoke doze simvastatinaMuscle adverse effects associated with high-dose simvastatin

Mario Ivanuša

Iako uporaba statina dokazano smanjuje učestalost neželjenih kardiovaskularnih događaja i produljuje život, učinak ovih lijekova može biti i manji od očekivanog ukoliko se primjenjuju niže doze od onih opisanih u kliničkim studijama, ako zbog genetskog defekta postoji neadekvatan biokemijski odgovor ili nastupe nepodnošljivost ili nuspojave. Pri primjeni simvastatina u dozi od 80 mg u odnosu na 20 mg registrirano je smanjenje relativnog rizika od kardiovaskularnih događaja, no uz povišen rizik mišićnih nuspojava. Sredinom 2011. godine Američka agencija za hranu i lijekove (FDA) donosi nove informacije o sigurnosti primjene simvastatina. 

Ključne riječi:
dislipidemije; inhibitori hidroksimetilglutaril-CoA reduktaze; nuspojave; sekundarna prevencija; simvastatin

Članak u cijelosti pročitajte u tiskanom izdanju MEDIX, God. 17 Br. 96

Evidence shows that statins reduce the incidence of unwanted cardiovascular events and increase life expectancy. However, these effects may be less pronounced if statins are administered in dosages lower than those described in clinical trials, especially in case of an inadequate biochemical response due to a genetic defect, intolerance or adverse reactions. A relative risk reduction for cardiovascular events was reported in patients receiving simvastatin 80 mg in comparison with those receiving simvastatin 20 mg, but the risk of muscle adverse effects was increased in the latter group. In mid-2011, the US Food and Drugs Administration released new information on the safety of simvastatin. 

Key words:
adverse effects; dyslipidemias; hydroxymethylglutaryl-CoA reductase inhibitors; secondary prevention; simvastatin